ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales

ARS Pharmaceuticals

09/03/2026 10:10

Overview

Biopharmaceutical firm's Q4 revenue beat analyst expectations

Company reported Q4 net loss of $41.3 mln

Company holds $245 mln in cash and investments to support operations

Outlook

ARS Pharma expects regulatory approval for neffy in Canada in Q2 2026

Result Drivers

NEFFY SALES - U.S. net product revenue from neffy reached $20.3 mln in Q4, contributing significantly to total revenue

PAYOR ACCESS - Progress with insurers has been positive, with efforts to secure unrestricted access to neffy continuing

Company press release: ID:nGNX6dbN79

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$28.1 mln
$25.58 mln (6 Analysts)
Q4 EPS
-$0.42
Q4 Net Income
-$41.3 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50, about 247.7% above its March 6 closing price of $9.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)